Regencell Bioscience Holdings ($RGC) Trading Volatility and Market Manipulation Risk Case

Investors can submit applications for the lead plaintiff role.

D. Maryland

Court

1:26-cv-01602

Case number

10/28/2024

Class period Start

10/31/2025

Class period End

06/23/2026

Lead Plaintiff motion deadline

$RGC investors filed a claim against Regencell Bioscience Holdings for allegedly downplaying unusual trading volatility and the risk that its shares were being affected by market manipulation.
After Regencell Bioscience Holdings disclosed a DOJ investigation into trading in its shares, $RGC fell 18.56% on November 3, 2025, closing at $13.56 per share.
$RGC investors can join this case to be notified about potential recovery.
Case Details:

Between October 28, 2024 and October 31, 2025, Regencell Bioscience Holdings told investors it was developing traditional Chinese medicine treatments for ADHD and autism spectrum disorder. Executives emphasized that the company’s formula aimed to treat the underlying cause of neurocognitive disorders, while its filings described stock volatility as tied mainly to short selling, short squeezes, and third-party media activity.

However, during this period, investors allege Regencell Bioscience Holdings was exposed to extreme and unexplained trading swings that were not tied to its business fundamentals. Regencell Bioscience Holdings allegedly failed to disclose that the company was vulnerable to or affected by market manipulation, that this volatility exposed investors to significant financial risk, and that the issue created heightened risk of government scrutiny, legal costs, penalties, and reputational harm.

Then, on October 31, 2025, the company revealed that it had received DOJ correspondence and a subpoena connected to an investigation into trading in its shares. $RGC fell $3.09, closing at $13.56. 

Additional revelations followed in the same disclosure, including that the DOJ requested documents and communications about trading and other corporate, financial, and accounting matters. 

By November 3, 2025, shares had dropped to $13.56, representing a total decline of 18.56% over the correction period.

Based on these events, $RGC investors filed a claim against Regencell Bioscience Holdings, alleging the company:
It hid serious risks tied to unusual trading in its shares.
It blamed volatility mainly on short selling and third-party media while allegedly omitting the risk of market manipulation and government scrutiny.
It caused investors to reassess the company when the DOJ trading investigation was revealed.
Investors argue Regencell Bioscience Holdings misled the market about the causes and risks of its extreme share-price volatility, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Price manipulation,

Omissions

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

11/03/2025

Filing date

04/24/2026

Lead Plaintiff Deadline

06/23/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.